Latest From Illumina Inc.
The coming of spring has seen the announcement of multiple executive moves in the Asia Pacific region, including a new CEO at Japan's Daiichi Sankyo, while WuXi Apptec and llumina have also made new appointments. Other personnel changes also take place at Shionogi Healthcare and the top of Japan's main regulatory agency.
The New Year is just a week old but the biopharma merger and acquisitions merry-go-round is already spinning furiously as Lilly now steps in with a proposal to buy Loxo.
Vitrakvi is effective against a wide variety of cancers driven by NTRK fusion. But finding the patients who will benefit will be a challenge, given there are expected to be only around 2,500 to 3,000 new cases in the US and testing for the mutation is uncommon.
Drug Discovery Tools
- Nanotechnology, Chips, etc.
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Illumina Inc.
- Senior Management
Francis deSouza, Pres. & CEO
Sam Samad, CFO
Mark Van Oene, SVP, Chief Commercial Officer
Garrett Hampton, PhD, EVP, Clinical Genomics
Omead Ostadan, EVP, Products & Ops
Mark Stapley, EVP, Strategy & Corp Dev
Mostafa Ronaghi, PhD, SVP, CTO
- Contact Info
Phone: (858) 202-4500
5200 Illumina Way
San Diego, CA 92122
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.